55 results about "Contraceptive Effect" patented technology

This invention relates to a method of producing an auto induced biological barrier against spermatozoids and / or other microorganisms including viruses and / or pre cancers or non invasive cancers involving the production of an autoimmune reaction in a host in need of such auto-inducement. The invention is characterized in that it comprises the steps of producing heat shock proteins inside vaginal and cervical mucosal cells and releasing said heat shock proteins into the vaginal cavity thus inducing an autoimmune response through a trigger and / or stimulation of both innate and adaptive systems and, as a consequence, the production of: a contraceptive effect through the elimination of the migration or free movement of individual or populations of spermatozoids and / or an inhibition of the maturation and / or capacitation process of the same and / or a neutralization or destruction of the same; a prophylactic effect through an elimination of the migration or free movement of individual or populations of other microorganisms including viruses and / or a neutralization or destruction of the same; a prophylactic effect against pre cancers; a therapeutic effect against non invasive cancers. The invention also relates to a device for using said method comprising a hollow body (1) provided with a heat source on the inside as well as with a means (13, 27) of removal of said hollow body from the vaginal or rectal cavity and a means (6, 8, 10) capable of exchanging heat originating from the hollow body.

The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.

The invention relates to contraceptive. The contraceptive is characterized by comprising the following components by mass in single dosage: 10-50mu g of gestodene, 1.5-10mg of nomegestrol, 0.2-0.5mg of levonorgestrel, 1-20mg of drospirenone, 0.5-10mg of cyproterone, 10-20mu g of ethinyloestradiol, 40-80g of saccharose and 5-20mu g of mestranol. The sum of the content of the ethinyloestradiol and the content of the mestranol is not more than 30mu g; and the sum of the content of the cyproterone, the content of the ethinyloestradiol and the content of the saccharose is 2-20mg. The contraceptive adopts the means that multiple progestational hormones and estrogenic hormones are mixed for use so as to reduce the estrogenic hormones, so that the obtained contraceptive can guarantee less injury to a human body under the condition with better contraceptive effect.